Head-to-head evidence
adalimumab-adbm (Cyltezo) vs adalimumab-fkjp (Hulio)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriatic Arthritis
Shared mechanism: TNF-alpha · full Psoriatic Arthritis pipeline
adalimumab-adbm (Cyltezo)
Marketed by Boehringer Ingelheim
NCT02137226 · Phase 3 · completed
The 645-participant study was randomized, double-blind, and active-controlled against US-licensed Humira, with ACR20 response as the primary clinical endpoint. The prespecified equivalence margins were met at both Week 12 and Week 24, so the comparison supports equivalent clinical response between BI 695501 and Humira.
adalimumab-fkjp (Hulio)
Marketed by Biocon
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: adalimumab-adbm (Cyltezo)'s landscape · adalimumab-fkjp (Hulio)'s landscape